Changing paradigm to target microglia in neurodegenerative diseases: from anti-inflammatory strategy to active immunomodulation

References

• Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer disease. Lancet Neurol. 2015;14:388–405.
   PubMed Web of Science ®Google Scholar
• Lawson LJ, Perry V, Dri PH, et al. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience. 1990;39:151–170.
   PubMed Web of Science ®Google Scholar
• Biber K, Owens T, Boddeke E. What is microglia neurotoxicity (not)? Glia. 2014;62:841–854.
   PubMed Web of Science ®Google Scholar
• Block ML, Zecca L, Hong J. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8:57–69.
   PubMed Web of Science ®Google Scholar
• Polazzi E, Monti B. Microglia and neuroprotection: from in vitro studies to therapeutic applications. Prog Neurobiol. 2010;92:293–215.
   PubMed Web of Science ®Google Scholar
• Salter MW, Beggs S. Sublime microglia: expanding roles for the guardians of the CNS. Cell. 2014;158:15–24.
   PubMed Web of Science ®Google Scholar
• Streit WJ, Xue QS. Life and death of microglia. J Neuroimmune Pharmacol. 2009;4:371–379.
   PubMed Web of Science ®Google Scholar
• Ginhoux F, Greter M, Leboeuf M, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330:841–845.
   PubMed Web of Science ®Google Scholar
• Elmore MR, Najafi AR, Koike MA, et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 2014;82(2):380–397.
   PubMed Web of Science ®Google Scholar
• Stanley ER, Chitu V. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb Perspect Biol. 2014;6(6).
   PubMed Web of Science ®Google Scholar
• Mizuno T, Doi Y, Mizoguchi H, et al. Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-β neurotoxicity. Am J Pathol. 2011;179(4):2016–2027.
   PubMed Web of Science ®Google Scholar
• Walton NM, Sutter BM, Laywell ED, et al. Microglia instruct subventricular zone neurogenesis. Glia. 2006;54:815–825.
   PubMed Web of Science ®Google Scholar
• Ziv Y, Ron N, Butovsky O, et al. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nature Neurosci. 2006;9:268–275.
   PubMed Web of Science ®Google Scholar
• Xie Z, Smith CJ, Van Eldik LJ. Activated microglia induce neuron death via MAP kinase signaling pathways involving JNK and p38. Glia. 2004;45:170–179.
   PubMed Web of Science ®Google Scholar
• Walker DG, Lue LE. Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer’s disease and other neurodegenerative diseases. J Neurosci. 2005;81:412–425.
   Web of Science ®Google Scholar
• Stence N1, Waite M, Dailey ME. Dynamics of microglial activation: a confocal time-lapse analysis in hippocampal slices. Glia. 2001;33(3):256–266.
   PubMed Web of Science ®Google Scholar
• Kozlowski C, Weimer RM. An automated method to quantify microglia morphology and application to monitor activation state longitudinally in vivo. PLoS One. 2012;7(2):e31814.
   PubMed Web of Science ®Google Scholar
• Vinet J, Weering HR, Heinrich A, et al. Neuroprotective function for ramified microglia in hippocampal excitotoxicity. J Neuroinflammation. 2012;9:27.
   PubMed Web of Science ®Google Scholar
• Ajami B, Bennet JL, Krieger C, et al. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci. 2007;10:1538–1543.
   PubMed Web of Science ®Google Scholar
• Hickey WE. Migration of hematogenous cells through the blood–brain barrier and the initiation of CNS inflammation. Brain Pathol. 1991;1:97–105.
   PubMed Web of Science ®Google Scholar
• Biswas SK, Mantovani A. Macrophage elasticity and interactions with lymphocyte subsets: cancer as a paradigm. Nat Immun. 2010;11:889–896.
   Google Scholar
• Gordon S, Martinez FO. Alternative activation of macrophages: mechanisms and functions. Immunity. 2010;32:593–604.
   PubMed Web of Science ®Google Scholar
• Clemente D, Ortega MC, Melero-Jerez C, et al. The effect of glia-glia interactions on oligodendrocyte precursor cell biology during development and in demyelinating diseases. Front Cell Neurosci. 2013;7:268.
   PubMed Web of Science ®Google Scholar
• Kigerl KA, Gensel JC, Ankeny DP, et al. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci. 2009;29(43):13435–13444.
   PubMed Web of Science ®Google Scholar
• Schechter R, Schwartz M. Harnessing monocyte-derived macrophages to control central nervous system pathologies: no longer “if” but “how”. J Pathol. 2013;229:332–346.
   PubMed Web of Science ®Google Scholar
• Browne TC, McQuillan K, McManus RM, et al. IFN-γ Production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer’s disease. J Immunol. 2013;190(5):2241–2251.
   PubMed Web of Science ®Google Scholar
• Fletcher JM, Lalor SJ, Sweeney CM, et al. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2010;162:1–11.
   PubMed Web of Science ®Google Scholar
• Schwartz M, Shechter R. Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev Neurol. 2101;6:405–410.
   Google Scholar
• Horsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol. 2009;8:382–397.
   PubMed Web of Science ®Google Scholar
• Teismann P, Ferger B. Inhibition of the cycloxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson’s disease. Synapse. 2001;39:167–174.
   PubMed Web of Science ®Google Scholar
• Chen H, Zhang SM, Hernan MA, et al. Nonsteroidal antiinflammatory drugs and the risk of Parkinson’s disease. Arch Neurol. 2003;60:1059–1064.
   PubMed Web of Science ®Google Scholar
• Gao X, Chen H, Schwarzschild MA, et al. Use of ibuprofen and risk of Parkinson disease. Neurology. 2011;76:863–869.
   PubMed Web of Science ®Google Scholar
• Rees K, Stowe R, Patel S, et al. Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson’s disease: evidence from observational studies. Cochrane Database Syst Rev. 2011;11:CD008454. DOI:10.1002/14651858.CD008454.pub2.
   Google Scholar
• Henkel JS, Beers DR, Zhao W, et al. Microglia in ALS: the good, the bad and the resting. Neuroimmune Pharmacol. 2009;4:389–398.
   PubMed Web of Science ®Google Scholar
• Drachman DB, Frank K, Dykes-Hober M, et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol. 2002;52:771–778.
   PubMed Web of Science ®Google Scholar
• Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002;417:74–78.
   PubMed Web of Science ®Google Scholar
• Gordon PH, Moore DH, Miller RG, Et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6:1045–1053.
   PubMed Web of Science ®Google Scholar
• Swash M. Learning from failed trials in ALS. Lancet Neurol. 2007;6:1034–1035.
   PubMed Web of Science ®Google Scholar
• Contestabile A. Amyotrophic lateral sclerosis: from research to therapeutic attempts and therapeutic perspectives. Curr Med Chem. 2011;18:5655–5665.
   PubMed Web of Science ®Google Scholar
• Peviani M, Caron I, Pizzasegola C, et al. Unraveling the complexity of amyotrophic lateral sclerosis: recent advances from the transgenic mutant SOD1 mice. CNS Neurol Disord Drug Targets. 2010;9(4):491–503.
   PubMed Web of Science ®Google Scholar
• Shoemaker JL, Seely KA, Reed RL, et al. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem. 2007;101:87–98.
   PubMed Web of Science ®Google Scholar
• Yiangou Y, Facer P, Durrenberger P, et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006;6:12.
   PubMed Web of Science ®Google Scholar
• De Lago E, Fernández-Ruiz J. Cannabinoids and neuroprotection in motor-related disorders. CNS Neurol Disord Drug Targets. 2007;6(6):377–387.
   PubMedGoogle Scholar
• Thériault P, ElAli A, Rivest S. The dynamics of monocytes and microglia in Alzheimer’s disease. Alzh Res Ther. 2015;7. doi:10.1186/s13195-015-0125-2.
   PubMed Web of Science ®Google Scholar
• Lim GP, Yang F, Chu T, et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging. 2001;22:983–991.
   PubMed Web of Science ®Google Scholar
• Biscaro B, Lindvall O, Tesco G, et al. Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimer’s disease. Neurodegener Dis. 2012;91:87–98.
   Google Scholar
• McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiological studies. Neurology. 1996;47:425–432.
   PubMed Web of Science ®Google Scholar
• The Alzheimer’s Disease Anti-inflammatory Prevention Trial Research Group. Results of a follow-up study to the randomized Alzheimer’s disease anti-inflammatory prevention trial (ADAPT). Alz Demen. 2013;9:714–723.
   PubMed Web of Science ®Google Scholar
• Jaturapatporn D, Isaac M, McCleery J, et al. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer’s disease (Review). Cochrane Database Syst Rev. 2012; Art. No.: CD006378. DOI:10.1002/14651858.CD006378.pub2.
   PubMed Web of Science ®Google Scholar
• Solas M, Francis PT, Franco R, et al. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer’s disease patients. Neurobiol Aging. 2013;34(3):805–808.
   PubMed Web of Science ®Google Scholar
• Aso E, Juvés S, Maldonado R, et al. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice. J Alzheimers Dis. 2013;35(4):847–858.
   PubMed Web of Science ®Google Scholar
• Pascual AC, Martín-Moreno AM, Giusto NM, et al. Normal aging in rats and pathological aging in human Alzheimer’s disease decrease FAAH activity: modulation by cannabinoid agonists. Exp Gerontol. 2014;60:92–99.
   PubMed Web of Science ®Google Scholar
• Lott IT, Head E. Down syndrome and Alzheimer’s disease: a link between development and aging. Ment Retard Dev Disabil Rev. 2001;7:172–178.
   PubMedGoogle Scholar
• Xue QS, Streit WJ. Microglial pathology in Down syndrome. Acta Neuropathol. 2011;122:455–466.
   PubMed Web of Science ®Google Scholar
• Hunter CL, Bachman D, Granholm A-C. Minocycline prevents cholinergic loss in a mouse model of Down’s syndrome. Ann Neurol. 2004;56:675–688.
   PubMed Web of Science ®Google Scholar
• Crotti A, Glass CK. The choreography of neuroinflammation in Huntington’s disease. Trends Immunol. 2015;36:364–373.
   PubMed Web of Science ®Google Scholar
• Norflus F, Nanje A, Gutekunst C-A, et al. Anti-inflammatory treatment with acetylsalicylate or refecoxib is not neuroprotective in Huntington’s disease transgenic mice. Neurobiol Dis. 2004;17:319–325.
   PubMed Web of Science ®Google Scholar
• Kumar A, Singh SK, Kumar V, et al. Huntington’s disease: an update of therapeutic strategies. Gene. 2015;556:91–97.
   PubMed Web of Science ®Google Scholar
• Hersch S, Fink K, Vonsattel JP, et al. Minocycline is protective in a mouse model of Huntington’s disease. Ann Neurol. 2003;54(6):841.
   PubMed Web of Science ®Google Scholar
• Menalled LB, Patry M, Ragland N, et al. Comprehensive behavioral testing in the R6/2 mouse model of Huntington’s disease shows no benefit from CoQ10 or minocycline. PLoS One. 2010;5(3):e9793.
   PubMed Web of Science ®Google Scholar
• Huntington Study Group DOMINO Investigators. A futility study of minocycline in Huntington’s disease. Mov Disord. 2010;25(13):2219–2224.
   PubMed Web of Science ®Google Scholar
• Popovic N, Schubart A, Goetz BD, et al. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol. 2002;51:215–223.
   PubMed Web of Science ®Google Scholar
• Nikodemova M, Watters JJ, Jackson SJ, et al. Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C (PKC)/betaII. J Biol Chem. 2007;282:15208–15216.
   PubMed Web of Science ®Google Scholar
• Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol. 2015. [Epub ahead of print].
   Web of Science ®Google Scholar
• Pepe G, Calderazzi G, De Maglie M, et al. Heterogeneous induction of microglia M2a phenotype by central administration of interleukin-4. J Neuroinflammation. 2014;11:211.
   PubMed Web of Science ®Google Scholar
• Kipnis J, Yoles E, Porat Z, et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci U S A. 2000;97(13):7446–7451.
   PubMed Web of Science ®Google Scholar
• Benner EJ, Mosley RL, Destache CJ, et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson’s disease. Proc Natl Acad Sci U S A. 2004;101(25):9435–9440.
   PubMed Web of Science ®Google Scholar
• Reynolds AD, Stone DK, Hutter JA, et al. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson’s disease. J Immunol. 2010;184(5):2261–2271.
   PubMed Web of Science ®Google Scholar
• Butovsky O, Koronyo-Hamaoui M, Kunis G, et al. Glatiramer acetate fights against Alzheimer’s disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci U S A. 2006;103(31):11784.
   PubMed Web of Science ®Google Scholar
• Haenggeli C, Julien JP, Mosley RL, et al. Therapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALS. Neurobiol Dis. 2007;26(1):146–152.
   PubMed Web of Science ®Google Scholar
• Meininger V, Drory VE, Leigh PN, et al. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler. 2009;10(5–6):378–383.
   PubMed Web of Science ®Google Scholar
• English C, Aloi JJ. New FDA-approved disease-modifying therapies for multiple sclerosis. Clin Ther. 2015;37(4):691–715.
   PubMed Web of Science ®Google Scholar
• Giunti D, Parodi B, Cordano C, et al. Can we switch microglia’s phenotype to foster neuroprotection? Focus Multiple Sclerosis Immunol. 2014;141(3):328–339.
   Google Scholar
• Chabot S, Yong FP, Le DM, et al. Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis. Mult Scler. 2002;8(4):299–306.
   PubMed Web of Science ®Google Scholar
• Pul R, Moharregh-Khiabani D, Škuljec J, et al. Glatiramer acetate modulates TNF-α and IL-10 secretion in microglia and promotes their phagocytic activity. J Neuroimmune Pharmacol. 2011;6(3):381–388.
   PubMed Web of Science ®Google Scholar
• Burness CB1, Deeks ED. Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis. CNS Drugs. 2014;28(4):373–387.
   PubMed Web of Science ®Google Scholar
• Wilms H, Sievers J, Rickert U, et al. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL- 1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation. 2010;7:30.
   PubMed Web of Science ®Google Scholar
• Foresti R, Bains SK, Pitchumony TS, et al. Small molecule activators of the Nrf2-HO-1 antioxidant axis modulate heme metabolism and inflammation in BV2 microglia cells. Pharmacol Res. 2013;76:132–148.
   PubMed Web of Science ®Google Scholar
• Wei Y, Yemisci M, Kim HH, et al. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol. 2011;69(1):119–129.
   PubMed Web of Science ®Google Scholar
• Noda H, Takeuchi H, Mizuno T, et al. Fingolimod phosphate promotes the neuroprotective effects of microglia. J Neuroimmunol. 2013;256(1–2):13–18.
   PubMed Web of Science ®Google Scholar
• Pawate S, Bagnato F. Newer agents in the treatment of multiple sclerosis. Neurologist. 2015;19(4):104–117.
   PubMed Web of Science ®Google Scholar
• Novartis [Internet]. Basel [CH]: novartis AG; c2015. Novartis provides update on fingolimod Phase III trial in primary progressive MS (PPMS); [ cited 2014 Dec 1]; [ about 8 screens]. Available from: https://www.novartis.com/news/media-releases/novartis-provides-update-fingolimod-phase-iii-trial-primary-progressive-ms-ppms
   Google Scholar
• Kolb-Sobieraj C, Gupta S, Weinstock-Guttman B. Laquinimod therapy in multiple sclerosis: a comprehensive review. Neurol Ther. 2014;3(1):29–39.
   PubMedGoogle Scholar
• Wild EJ, Tabrizi SJ. Targets for future clinical trials in Huntington’s disease: what’s in the pipeline? Mov Disord. 2014;29(11):1434–1445.
   PubMed Web of Science ®Google Scholar
• Huh SH, Chung YC, Piao Y, et al. Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson’s disease. J Immunol. 2011;187(2):960–969.
   PubMed Web of Science ®Google Scholar
• Shin JH, Kim ID, Kim SW, et al. Ethyl pyruvate inhibits HMGB1 phosphorylation and release by chelating calcium. Mol Med. 2015;20:649–657.
   PubMed Web of Science ®Google Scholar
• Takata K, Kitamura Y, Tsuchiya D, et al. High mobility group box protein-1 inhibits microglial Abeta clearance and enhances Abeta neurotoxicity. J Neurosci Res. 2004;78(6):880–891.
   PubMed Web of Science ®Google Scholar
• Gao HM, Zhou H, Zhang F, et al. HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci. 2011;31(3):1081–1092.
   PubMed Web of Science ®Google Scholar
• Mollica L, Marchis FD, Spitaleri A, et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol. 2007;14:431–441.
   PubMed Web of Science ®Google Scholar
• Lee S, Nam Y, Koo JY, et al. A small molecule binding HMGB1 and HMGB2 inhibits microglia-mediated neuroinflammation. Nat Chem Biol. 2014;10(12):1055–1060.
   PubMed Web of Science ®Google Scholar
• Giri S, Nath N, Smith B, et al. 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J Neurosci. 2004;24(2):479–487.
   PubMed Web of Science ®Google Scholar
• Lu DY, Tang CH, Chen YH, et al. Berberine suppresses neuroinflammatory responses through AMP-activated protein kinase activation in BV-2 microglia. J Cell Biochem. 2010;110(3):697–705.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang X, Wang C, et al. Neuroprotection of early and short-time applying berberine in the acute phase of cerebral ischemia: up-regulated pAkt, pGSK and pCREB, down-regulated NF-κB expression, ameliorated BBB permeability. Brain Res. 2012;1459:61–70.
   PubMed Web of Science ®Google Scholar
• Haghani M, Shabani M, Tondar M. The therapeutic potential of berberine against the altered intrinsic properties of the CA1 neurons induced by Aβ neurotoxicity. Eur J Pharmacol. 2015;758:82–88.
   PubMed Web of Science ®Google Scholar
• Chen CC, Hung TH, Lee CY, et al. Berberine protects against neuronal damage via suppression of glia-mediated inflammation in traumatic brain injury. PLoS One. 2014;9(12):e115694.
   PubMed Web of Science ®Google Scholar
• Jin Q, Cheng J, Liu Y, et al. Improvement of functional recovery by chronic metformin treatment is associated with enhanced alternative activation of microglia/macrophages and increased angiogenesis and neurogenesis following experimental stroke. Brain Behav Immun. 2014;40:131–142.
   PubMed Web of Science ®Google Scholar
• Zhu XC, Jiang T, Zhang QQ, et al. Chronic metformin preconditioning provides neuroprotection via suppression of NF-κB-mediated inflammatory pathway in rats with permanent cerebral ischemia. Mol Neurobiol. 2015;52(1):375–385.
   PubMed Web of Science ®Google Scholar
• Zhang F, Liu J, Shi JS. Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. Eur J Pharmacol. 2010;636(1–3):1–7.
   PubMed Web of Science ®Google Scholar
• Wang F, Cui N, Yang L, et al. Resveratrol rescues the impairments of hippocampal neurons stimulated by microglial over-activation In vitro. Cell Mol Neurobiol. 2015;35(7):1003–1015.
   Web of Science ®Google Scholar
• Yuskaitis CJ, Jope RS. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal. 2009;21(2):264–273.
   PubMed Web of Science ®Google Scholar
• Kondratiuk I, Devijver H, Lechat B, et al. Glycogen synthase kinase-3beta affects size of dentate gyrus and species-typical behavioral tasks in transgenic and knockout mice. Behav Brain Res. 2013;248:46–50.
   PubMed Web of Science ®Google Scholar
• Kimura T, Yamashita S, Nakao S, et al. GSK-3beta is required for memory reconsolidation in adult brain. PLoS One. 2008;3(10):e3540.
   PubMed Web of Science ®Google Scholar
• Palomo V, Perez DI, Perez C, et al. 5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3. J Med Chem. 2012;55(4):1645–1661.
   PubMed Web of Science ®Google Scholar
• Morales-García JA, Susín C, Alonso-Gil S, et al. Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. ACS Chem Neurosci. 2013;4(2):350–360.
   PubMed Web of Science ®Google Scholar
• Prati F, De Simone A, Bisignano P, et al. Multitarget drug discovery for Alzheimer’s disease: triazinones as BACE-1 and GSK-3β inhibitors. Angew Chem Int Ed Engl. 2015;54(5):1578–1582.
   PubMed Web of Science ®Google Scholar
• Prati F, De Simone A, Armirotti A, et al. 3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the first dual BACE-1/GSK-3β fragment hits against Alzheimer’s disease. ACS Chem Neurosci. 2015;6(10):1665–1682.
   PubMed Web of Science ®Google Scholar
• Serenó L, Coma M, Rodríguez M, et al. A novel GSK-3beta inhibitor reduces Alzheimer’s pathology and rescues neuronal loss in vivo. Neurobiol Dis. 2009;35(3):359–367.
   PubMed Web of Science ®Google Scholar
• Onishi T, Iwashita H, Uno Y, et al. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer’s disease. J Neurochem. 2011;119(6):1330–1340.
   PubMed Web of Science ®Google Scholar
• Lovestone S, Boada M, Dubois B, et al. ARGO investigators. A phase II trial of tideglusib in Alzheimer’s disease. J Alzheimers Dis. 2015;45(1):75–88.
   PubMed Web of Science ®Google Scholar
• Koh SH, Kim Y, Kim HY, et al. Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS. Exp Neurol. 2007;205(2):336–346.
   PubMed Web of Science ®Google Scholar
• Ahn SW, Jeon GS, Kim MJ, et al. Neuroprotective effects of JGK-263 in transgenic SOD1-G93A mice of amyotrophic lateral sclerosis. J Neurol Sci. 2014;340(1–2):112–116.
   PubMed Web of Science ®Google Scholar
• Suuronen T, Huuskonen J, Pihlaja R, et al. Regulation of microglial inflammatory response by histone deacetylase inhibitors. J Neurochem. 2003;87(2):407–416.
   PubMed Web of Science ®Google Scholar
• Suuronen T, Huuskonen J, Nuutinen T, et al. Characterization of the pro-inflammatory signaling induced by protein acetylation in microglia. Neurochem Int. 2006 ;49(6):610–618.
   PubMed Web of Science ®Google Scholar
• Chen PS, Wang CC, Bortner CD, et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience. 2007;149(1):203–212.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Rowe M, Ren M, et al. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther. 2007;321(3):892–901.
   PubMed Web of Science ®Google Scholar
• Faraco G, Pittelli M, Cavone L, et al. Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Neurobiol Dis. 2009;36(2):269–279.
   PubMed Web of Science ®Google Scholar
• Chen SH, Wu HM, Ossola B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage. Br J Pharmacol. 2012;165(2):494–505.
   PubMed Web of Science ®Google Scholar
• Wang G, Shi Y, Jiang X, et al. HDAC inhibition prevents white matter injury by modulating microglia/macrophage polarization through the GSK3β/PTEN/Akt axis. Proc Natl Acad Sci U S A. 2015;112(9):2853–2858.
   PubMed Web of Science ®Google Scholar
• Chen YC, Wu JS, Tsai HD, et al. Peroxisome proliferator- activated receptor gamma (PPAR-γ) and neurodegenerative disorders. Mol Neurobiol. 2012;46(1):114–124.
   PubMed Web of Science ®Google Scholar
• Masciopinto F, Di Pietro N, Corona C, et al. Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice. Cell Death Dis. 2012;3:e448.
   PubMed Web of Science ®Google Scholar
• Savage JC, Jay T, Goduni E, et al. Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer’s disease. J Neurosci. 2015;35(16):6532–6543.
   PubMed Web of Science ®Google Scholar
• Barbiero JK, Santiago RM, Persike DS, et al. Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine. Behav Brain Res. 2014;274:390–399.
   PubMed Web of Science ®Google Scholar
• Pisanu A, Lecca D, Mulas G, et al. Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson’s disease. Neurobiol Dis. 2014;71:280–291.
   PubMed Web of Science ®Google Scholar
• NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson’s disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015;14(8):795–803.
   PubMed Web of Science ®Google Scholar
• Schütz B, Reimann J, Dumitrescu-Ozimek L, et al. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci. 2005;25(34):7805–7812.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Dengler R, Heneka MT, et al.; GERP ALS Study Group. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One. 2012;7(6):e37885.
   PubMed Web of Science ®Google Scholar
• Feinstein DL, Galea E, Gavrilyuk V, et al. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol. 2002;51(6):694–702.
   PubMed Web of Science ®Google Scholar
• Chen SH, Oyarzabal EA, Hong JS. Critical role of the Mac1/NOX2 pathway in mediating reactive microgliosis-generated chronic neuroinflammation and progressive neurodegeneration. Curr Opin Pharmacol. 2015;26:54–60.
   PubMed Web of Science ®Google Scholar
• Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl Neurodegener. 2015;4:19.
   PubMed Web of Science ®Google Scholar
• Von Bernhardi R, Eugenín-von Bernhardi L, Eugenín J. Microglial cell dysregulation in brain aging and neurodegeneration. Front Aging Neurosci. 2015;7:124.
   PubMed Web of Science ®Google Scholar